Crystal Structures of Human 108V and 108M Catechol O-Methyltransferase

Journal of Molecular Biology

Volumn 380, Issue 1, 2008, Pages 120-130

  Rutherford, K ^a   Le Trong, I ^a   Stenkamp, R E ^a   Parson, W W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

catechol O methyltransferase; crystallography; Parkinson's disease; protein structure; single nucleotide polymorphism

Indexed keywords

3,5 DINITROCATECHOL; CATECHOL DERIVATIVE; CATECHOL METHYLTRANSFERASE; CYSTEINE; METHIONINE; S ADENOSYLMETHIONINE; SOLVENT; VALINE;

ARTICLE; ATOM; BINDING SITE; CRYSTAL STRUCTURE; DISULFIDE BOND; ENZYME ACTIVE SITE; ENZYME POLYMORPHISM; ENZYME STABILITY; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; HYDROPHOBICITY; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN SECONDARY STRUCTURE; PROTEIN VARIANT; SOLUBILITY;

RATTUS;

EID: 44649191697     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.04.040     Document Type: Article

References (85)

1. Axelrod J., and Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 233 (1958) 702-705
2. Männistö P.T., and Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 51 (1999) 593-628
3. Weinshilboum R.M., Otterness D.M., and Szumlanski C.L. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 19-52
4. Huh M.M., and Friedhoff A.J. Multiple molecular forms of catechol-O-methyltransferase. Evidence for two distinct forms, and their purification and physical characterization. J. Biol. Chem. 254 (1979) 299-308
5. Tenhunen J., Salminen M., Jalanko A., Ukkonen S., and Ulmanen I. Structure of the rat catechol-O-methyltransferase gene. Separate promoters are used to produce messenger RNAs for soluble and membrane-bound forms of the enzyme. DNA Cell Biol. 12 (1993) 253-263
6. Tenhunen J., Salminen M., Lundstrom K., Kiviluoto T., Savolainen R., and Ulmanen I. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur. J. Biochem. 223 (1994) 1049-1059
7. Bai H.-W., Shim J.-Y., Yu J., and Zhu B.T. Biochemical and molecular modeling studies of the O-methylation of various endogenous and exogenous catechol substrates catalyzed by recombinant human soluble and membrane-bound catechol-O-methyltransferases. Chem. Res. Toxicol. 20 (2007) 1409-1425
8. Vidgren J., Svensson L., and Lundstrom K. Crystal structure of catechol O-methyltransferase. Nature 364 (1994) 354-358
9. Lerner C., Ruf A., Gramlich V., Masjost B., Zuercher G., Jakob-Roetne R., et al. X-ray crystal structure of a bisubstrate inhibitor bound to the enzyme catechol-O-methyltransferase: a dramatic effect of inhibitor preorganization on binding affinity. Angew. Chem., Int. Ed. 40 (2001) 4040-4042
10. Bonifácio M.J., Archer M., Rodrigues M.L., Matias P.M., Learmonth D.A., Carrondo M.A., et al. Kinetics and crystal structure of catechol-O-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application. Mol. Pharmacol. 62 (2002) 795-805
11. Lerner C., Masjost B., Ruf A., Gramlich V., Jakob-Roetne R., Zurcher G., et al. Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity. Org. Biomol. Chem. 1 (2003) 42-49
12. Palma P.N., Rodrigues M.L., Archer M., Bonifacio M.J., Loureiro A.I., Learmonth D.A., et al. Comparative study of ortho- and meta-nitrated inhibitors of catechol-O-methyltransferase: interactions with the active site and regioselectivity of O-methylation. Mol. Pharmacol. 70 (2006) 143-153
13. Cheng X., and Roberts R.J. AdoMet-dependent methylation, DNA methyltransferases and base flipping. Nucleic Acids Res. 29 (2001) 3784-3795
14. Martin J.L., and McMillan F.M. SAM (dependent) I AM: the S-adenosylmethionine-dependent methyltransferase fold. Curr. Opin. Struct. Biol. 12 (2002) 783-793
15. Kaakkola S., Gordin A., and Männistö P.T. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen. Pharmacol. 25 (1994) 813-824
16. Masjost B., Ballmer P., Borroni E., Zurcher G., Winkler F.K., Jakob-Roetne R., et al. Structure-based design, synthesis and in vitro evaluation of bisubstrate inhibitors for catechol-O-methyltransferase (COMT). Chemistry 6 (2000) 971-982
17. Palma P.N., Bonifacio M.J., Loureiro A.I., Wright L.C., Learmonth D.A., and Soares-Da-Silva P. Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor. Drug Metab. Dispos. 31 (2003) 250-258
18. Tervo A.J., Nyronen T.H., Ronkko T., and Poso A. A structure-activity relationship study of catechol-O-methyltransferase inhibitors combining molecular docking and 3D QSAR methods. J. Comput. Aided Mol. Des. 17 (2003) 797-810
19. Learmonth D.A., Palma P.N., Vieria-Coehlo M.A., and Soares-Da-Silva P. Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. J. Med. Chem. 47 (2004) 6207-6217
20. Learmonth D.A., Bonifácio M.J., and Soares-Da-Silva P. Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. J. Med. Chem. 48 (2005) 8070-8078
21. Lautala P., Ulmanen I., and Taskinen J. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol. Pharmacol. 59 (2001) 393-402
22. Bertocci B., Miggiano V., Da Prada M., Dembic Z., Lahm H.-W., and Malherbe P. Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form. Proc. Natl Acad. Sci. USA 88 (1991) 1416-1420
23. Lundström K., Salminen M., Jalanko A., Savolainen R., and Ulmanen I. Cloning, expression and structure of catechol-O-methyltransferase. Biochim. Biophys. Acta 1251 (1995) 1-10
24. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., and Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6 (1996) 243-250
25. Weinshilboum R.M., and Raymond F.A. Inheritance of low erythrocyte catechol-O-methyltransferase activity in man. Am. J. Med. Genet. 29 (1977) 125-135
26. Palmatier M.A., Kang A.M., and Kidd K.K. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol. Psychiatry 46 (1999) 557-567
27. Goodman J.E., Jensen L.T., He P., and Yager J.D. Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. Pharmacogenetics 12 (2002) 517-528
28. Dawling S., Roodi N., Mernaugh R.L., Wang X., and Parl F.F. Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res. 61 (2001) 6716-6722
29. Yim D.-S., Park S.K., Yoo K.-Y., Yoon K.S., Chung H.H., Kang H.L., et al. Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics 11 (2001) 279-286
30. Wedren S., Rudqvist T.R., Granath F., Weiderpass E., Ingelman-Sundberg M., Persson I., et al. Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. Carcinogenesis 24 (2003) 681-687
31. Karayiorgou M., Altemus M., Galke B.L., Goldman D., Murphy D.L., Ott J., et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc. Natl Acad. Sci. USA 94 (1997) 4572-4575
32. Karayiorgou M., Sobin C., Blundell M.L., Galke B.L., Malinova L., Goldberg P., et al. Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. Biol. Psychiatry 45 (1999) 1178-1189
33. Nolan K.A., Volavka J., Czobor P., Cseh A., Lachman H., Saito T., et al. Suicidal behavior in patients with schizophrenia is related to COMT polymorphism. Psychiatr. Genet. 10 (2000) 117-124
34. Lachman H.M., Nolan K.A., Mohr P., Saito T., and Volavka J. Association between catechol O-methyltransferase genotype and violence in schizophrenia and schizoaffective disorder. Am. J. Psychiatry 155 (1998) 835-837
35. Strous R.D., Bark N., Parsia S.S., Volavka J., and Lachman H.M. Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behavior. Psychiatry Res. 69 (1997) 71-77
36. Strous R.D., Nolan K.A., Lapidus R., Diaz L., Saito T., and Lachman H.M. Aggressive behavior in schizophrenia is associated with the low enzyme activity COMT polymorphism: a replication study. Am. J. Med. Genet. 120B (2003) 29-34
37. Lachman H.M., Morrow B., Shprintzen R., Veit S., Parsia S.S., Faedda G., et al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am. J. Med. Genet. 67 (1996) 468-472
38. 158met genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science 299 (2003) 1240-1243
39. Diatchenko L., Slade G.D., Nackley A.G., Bhalang K., Sigurdsson A., Belfer I., et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum. Mol. Genet. 14 (2005) 135-143
40. Meyer-Lindenberg A., Kohn P.D., Kolachana B., Kippenhan S., McInerney-Leo A., Nussbaum R., et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat. Neurosci. 8 (2005) 594-596
41. Goldberg T.E., Egan M.F., Gscheidle T., Coppola R., Weickert T., Kolachana B.S., et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch. Gen. Psychiatry 60 (2003) 889-896
42. Scambler P.J. The 22q11 deletion syndromes. Hum. Mol. Genet. 9 (2000) 2421-2426
43. Graf W.D., Unis A.S., Yates C.M., Sulzbacher S., Dinulos M.B., Jack R.M., et al. Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism. Neurology 57 (2001) 410-416
44. Shifman S., Bronstein M., Sternfeld M., Pisante-Shalom A., Lev-Lehman E., Weizman A., et al. A highly significant association between a COMT haplotype and schizophrenia. Am. J. Hum. Genet. 71 (2002) 1296-1302
45. Bray N.J., Buckland P.R., Williams N.M., Williams H.J., Norton N., Owen M.J., et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am. J. Hum. Genet. 73 (2003) 152-161
46. Shifman S., Bronstein M., Sternfeld M., Pisanté A., Weizman A., Reznik I., et al. COMT: a common susceptibility gene in bipolar disorder and schizophrenia. Am. J. Med. Genet. 128B (2004) 61-64
47. Horowitz A., Shifman S., Rivlin N., Pisante A., and Darvasi A. Further tests of the association between schizophrenia and single nucleotide polymorphism markers at the catechol-O-methyltransferase locus in an Ashkenazi Jewish population using microsatellite markers. Psychiatr. Genet. 15 (2005) 163-169
48. Williams H.J., Owen M.J., and O'Donovan M.C. Is COMT a susceptibility gene for schizophrenia?. Schizophr. Bull. 33 (2007) 635-641
49. Rutherford K., Bennion B.J., Parson W.W., and Daggett V. The 108M polymorph of human catechol O-methyltransferase is prone to deformation at physiological temperatures. Biochemistry 45 (2006) 2178-2188
50. Lotta T., Vidgren J., Tilgmann C., Ullmanen I., Melén K., Julkunen I., et al. Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34 (1995) 4202-4210
51. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75 (2004) 807-821
52. Scanlon P.D., Raymond F.A., and Weinshilboum R.A. Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for the allele for low activity. Science 203 (1979) 63-65
53. Spielman R.S., and Weinshilboum R.M. Genetics of red cell COMT activity: analysis of thermal stability and family data. Am. J. Med. Genet. 10 (1981) 279-290
54. Weinshilboum R.M., and Dunnette J. Thermal stability and the biochemical genetics of erythrocyte catechol-O-methyl-transferase and plasma dopamine-beta-hydroxylase. Clin. Genet. 19 (1981) 426-437
55. Boudikova B., Szumlanski C., Maidak B., and Weinshilboum R.M. Human liver catechol-O-methyltransferase: pharmacogenetics. Clin. Pharmacol. Ther. 48 (1990) 381-389
56. Grossman M.H., Szumlanski C., Littrell J.B., Weinstein R., and Weinshilboum R. Electrophoretic analysis of low and high activity forms of catechol-O-methyltransferase in human erythrocytes. Life Sci. 50 (1992) 473-480
57. Aksoy S., Klener J., and Weinshilboum R.M. Catechol-O-methyltransferase pharmacogenetics: photoaffinity labelling and Western blot analysis of human liver samples. Pharmacogenetics 3 (1993) 116-122
58. Cotton N.J.H., Stoddard B., and Parson W.W. Oxidative inhibition of human soluble catechol-O-methyltransferase. J. Biol. Chem. 279 (2004) 23710-23718
59. Shield A.J., Thomae B.A., Eckloff B.W., Wieben E.D., and Weinshilboum R.M. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol. Psychiatry 9 (2004) 151-160
60. Li Y., Yao J., Chang M., Nikolic D., Yu L., Yager J.D., et al. Equine catechol estrogen 4-hydroxyequilenin is a more potent inhibitor of the variant form of catechol-O-methyltransferase. Chem. Res. Toxicol. 17 (2004) 512-520
61. Li Y., Yang X., Chang M., Yager J.D., Breemen R.B., and Bolton J.L. Functional and structural comparisons of cysteine residues in the Val108 wild type and Met108 variant of human soluble catechol O-methyltransferase. Chem. Biol. Interact. 152 (2005) 151-163
62. Rutherford, K., Alphandéry, E., McMillan, A., Daggett, V., & Parson W. W. The V108M mutation decreases the structural stability of catechol O-methyltransferase. Biochim. Biophys. Acta Proteins and Proteomics. In press. doi:10.1016/bbapap.2008.04.006.
63. Doyle A.E., Goodman J.E., Silber P.M., and Yager J.D. Catechol-O-methyltransferase low activity genotype (COMTLL) is associated with low levels of COMT protein in human hepatocytes. Cancer Lett. 214 (2004) 189-195
64. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblat D.M., Meng E.C., et al. UCSF Chimera-a visualization system for explo$32#$32#ratory research and analysis. J. Comput. Chem. 25 (2004) 1605-1612
65. Kraulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24 (1991) 946-950
66. Merritt E.A., and Bacon D.J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277 (1997) 505-524
67. Brunger A.T. Assessment of phase accuracy by cross-validation: the free R-value. Methods and applications. Acta Crystallogr., Sect. D: Biol. Crystallogr. 49 (1993) 24-36
68. Yao J., Li Y., Chang M., Wu H., Yang X., Goodman J.E., et al. Catechol estrogen 4-hydroxyequilenin is a substrate and an inhibitor of catechol-O-methyltransferase. Chem. Res. Toxicol. 16 (2003) 668-675
69. Vilbois F., Caspers P., Da Prada M., Lang G., Karrer C., Lahm H.-W., et al. Mass spectrometric analysis of human soluble catechol O-methyltransferase expressed in Escherichia coli. Identification of a product of ribosomal frameshifting and of reactive cysteines involved in S-adenosyl-l-methionine binding. Eur. J. Biochem. 222 (1994) 377-386
70. Wu H., Horton J.R., Battaile K., Allali-Hassani A., Martin F., Zeng H., et al. Structural basis of allele variation of human thiopurine-S-methyltransferase. Proteins 67 (2007) 198-208
71. Horton J.R., Sawada K., Nishibori M., Zhang X., and Cheng X. Two polymorphic forms of human histamine methyltransferase: structural, thermal, and kinetic comparisons. Structure 9 (2001) 837-849
72. Horton J.R., Sawada K., Nishibori M., and Cheng X. Structural basis for inhibition of histamine N-methyltransferase by diverse drugs. J. Mol. Biol. 353 (2005) 334-344
73. Tai H.L., Krynetski E.Y., Schuetz E.G., Yanishevski Y., and Evans W.E. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT* 2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl Acad. Sci. USA 94 (1997) 6444-6449
74. Tai H.L., Fessing M.Y., Bonten E.J., Yanishevski Y., d'Azzo A., Krynetski E.Y., et al. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT* 3A, TPMT*3B or TPMT*3C. Pharmacogenetics 9 (1999) 641-650
75. Wang L., Nguyen T.V., McLaughlin R.W., Sikkink L.A., Ramirez-Alvarado M., and Weinshilboum R. Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc. Natl Acad. Sci. USA 102 (2005) 9394-9399
76. Scott M.C., Van Loon J.A., and Weinshilboum R. Pharmacogenetics of N-methylation: heritability of human erythrocyte histamine N-methyltransferase activity. Clin. Pharmacol. Ther. 43 (1988) 256-262
77. Rutherford K., Parson W.W., and Daggett V. The histamine N-methyltransferase T105I polymorphism affects active site structure and dynamics. Biochemistry 47 (2008) 893-901
78. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
79. Vagin A., and Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30 (1997) 1022-1025
80. Murshudov G.N., Vagin A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 53 (1997) 240-255
81. McRee D.E. XtalView/Xfit-a versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125 (1999) 156-165
82. Harding M.M. Metal-ligand geometry relevant to proteins and in proteins: sodium and potassium. Acta Crystallogr., Sect. D: Biol. Crystallogr. 58 (2002) 872-874
83. Harding M.M. Small revisions to predicted distances around metal sites in proteins. Acta Crystallogr., Sect. D: Biol. Crystallogr. 62 (2006) 678-682
84. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35 (2007) W375-W383
85. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., et al. The Protein Data Bank. Nucleic Acids Res. 28 (2000) 235-242